Neuronetics (STIM) Set to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is set to post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Neuronetics to post earnings of ($0.23) per share for the quarter. Neuronetics has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. The company had revenue of $16.45 million during the quarter, compared to analysts’ expectations of $18.76 million. During the same period in the prior year, the business posted ($0.17) earnings per share. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Price Performance

STIM stock traded up $0.04 during trading on Tuesday, hitting $1.13. The stock had a trading volume of 125,782 shares, compared to its average volume of 243,749. The company’s 50-day moving average price is $0.88 and its two-hundred day moving average price is $1.66. Neuronetics has a twelve month low of $0.66 and a twelve month high of $5.07. The stock has a market capitalization of $34.10 million, a P/E ratio of -1.00 and a beta of 2.21. The company has a debt-to-equity ratio of 2.38, a current ratio of 2.58 and a quick ratio of 2.37.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on STIM shares. JMP Securities cut their price objective on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 14th. Canaccord Genuity Group reduced their price objective on Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Finally, William Blair reiterated a “market perform” rating on shares of Neuronetics in a research note on Monday, August 12th.

Insider Activity at Neuronetics

In related news, Director Robert Cascella purchased 35,000 shares of Neuronetics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $1.06 per share, with a total value of $37,100.00. Following the completion of the transaction, the director now directly owns 349,098 shares in the company, valued at approximately $370,043.88. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased 211,776 shares of company stock valued at $175,170 in the last ninety days. Insiders own 9.80% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.